Medical Technology

@xconomy.com 3 years ago

FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures

@xconomy.com 3 years ago

Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact

@xconomy.com 4 years ago

FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes

@xconomy.com 4 years ago

Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy

@xconomy.com 4 years ago

Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal

@xconomy.com 4 years ago

FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades

@xconomy.com 4 years ago

Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug

@xconomy.com 5 years ago

At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments

@xconomy.com 5 years ago

After Scoring New Capital, Fifth Eye Prepares to Seek FDA Approval

@xconomy.com 5 years ago

Sage Hits Mark in Postpartum Depression Phase 3 Trial, Stock Surges

@xconomy.com 5 years ago

Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug

@xconomy.com 5 years ago

Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines

@xconomy.com 5 years ago

Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines